Login to Your Account



D-mab's Osteo Clock Ticking, Cancer-Bone Loss BLA Filed

By Randy Osborne


Monday, May 17, 2010
Waiting for FDA word on the approval of denosumab in postmenopausal osteoporosis, Amgen Inc. as expected has filed a biologics license application seeking approval of the highly touted subcutaneous RANK ligand inhibitor in preventing skeletal-related events (SREs) in advanced cancer patients. The news was disclosed late Friday afternoon. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription